ALL-IN-ONE SKIN-BRIGHTENING FORMULATIONS

Abstract

Certain dermatological formulations for direct skin application that correct for hyperpigmentation effects are provided. Such formulations include a number of different compounds that work synergistically to effectuate multiple and varied pathways to pigment removal and/or brightening within the dermal layer. The ability to do so without the necessity for hydroquinone, and thus with a suitable composition that is safe for handling and utilization by pregnant and nursing women, is accorded through a combination of specific ingredients in limited proportional ranges, as well. Such ingredients include kojic acid, niacinamide, sodium hyaluraonate, tocopherol, and licorice extract in very narrow ranges proportionally within an aqueous serum. The method of manufacture and use thereof such formulations are encompassed within the invention as well.

Claims

1. An all-in-one skin treatment formulation comprising a base composition of ingredients of: from 92 to 96% by weight of water; from 0.0001 to 2% by weight of Kojic Acid; from 0.05 to 0.15% by weight of Niacinamide; from 0.8 to 1.2% by weight of Sodium Hyaluronate; from 0.008 to 0.012% by weight of Licorice Extract; and from 0.08 to 0.012% by weight of Tocopherol; and, as further components, from 0 to 5% by weight of a biomimetic encapsulated whitening peptide, from 0 to 0.01% by weight of Retinol, from 0 to 1.1% by weight of preservatives, from 0 to 2.5% of lactic acid, from 0 to 2.5% of glycolic acid, and from 0 to 2% by weight of Hydroquinone.

2. The formulation of claim 1 wherein said Hydroquinone is present.

3. The formulation of claim 1 wherein biomimetic encapsulated whitening peptide is present.

4. The formulation of claim 1 wherein said lactic acid, said glycolic acid, and said preservatives are present, and said Hydroquinone is not present.

5. The formulation of claim 3 wherein said Retinol is present and said Hydroquinone is not present.

6. The formulation of claim 2 wherein said Retinol is present and no other alternative components are present.

7. The formulation of claim 4 wherein neither said Retinol nor said biomimetic encapsulated whitening peptide are present.

8. A method of providing a skin brightening effect to an area of human skin exhibiting hyperpigmentation, said method comprising the steps of: a) providing the formulation of claim 1; and b) applying said formulation to said area of human skin.

9. A method of providing a skin brightening effect to an area of human skin exhibiting hyperpigmentation, said method comprising the steps of: a) providing the formulation of claim 2; and b) applying said formulation to said area of human skin.

10. A method of providing a skin brightening effect to an area of human skin exhibiting hyperpigmentation, said method comprising the steps of: a) providing the formulation of claim 3; and b) applying said formulation to said area of human skin.

11. A method of providing a skin brightening effect to an area of human skin exhibiting hyperpigmentation, said method comprising the steps of: a) providing the formulation of claim 4; and b) applying said formulation to said area of human skin.

12. A method of providing a skin brightening effect to an area of human skin exhibiting hyperpigmentation, said method comprising the steps of: a) providing the formulation of claim 5; and b) applying said formulation to said area of human skin.

13. A method of providing a skin brightening effect to an area of human skin exhibiting hyperpigmentation, said method comprising the steps of: a) providing the formulation of claim 6; and b) applying said formulation to said area of human skin.

14. A method of providing a skin brightening effect to an area of human skin exhibiting hyperpigmentation, said method comprising the steps of: a) providing the formulation of claim 7; and b) applying said formulation to said area of human skin.

Description

DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0029] The following examples are not intended to provide any limitation to the scope and bounds of the disclosure herein. The blends were made in accordance with the batch methods described above.

Formulations

Example 1

Chemical Brightening Complex Blend with Hydroquinone

[0030]

TABLE-US-00001 Ingredient (*indicates base composition component) % (by weight) Water* 95.78 Kojic Acid* 0.0001 Niacinamide* 0.10 Sodium Hyaluronate* 1.00 Licorice Extract* 0.01 Tocopherol* 0.10 Hydroquinone 2.00 Retinol 0.01 Phenoxyethanol 1.00

Example 2

Brightening Complex Blend with Beta-White

[0031]

TABLE-US-00002 Ingredient (*indicates base composition component) % (by weight) Water* 92.78 Kojic Acid* 2.00 Niacinamide* 0.10 Sodium Hyaluronate* 1.00 Licorice Extract* 0.01 Tocopherol* 0.10 Beta-White ™ 5.00 Retinol 0.01

Example 3

Brightening Complex for Pregnant Patients

[0032]

TABLE-US-00003 Ingredient (*indicates base composition component) % (by weight) Water* 92.79 Kojic Acid* 1.00 Niacinamide* 0.10 Sodium Hyaluronate* 1.00 Licorice Extract* 0.01 Tocopherol* 0.10 Glycolic Acid 2.50 Lactic Acid 2.50 Malic Acid 0.0001 Azealic Acid 0.0001 Salicyclic Acid 0.0001

Testing Protocols

[0033] Each formulation above was then introduced within a batch composition to dilute to a suitable concentration for a resultant serum and then tested on individual subjects. Each human female test subject was treated with an application of roughly 5 mL of the resultant serum on a specific skin area exhibiting hyperpigmentation. The application was made daily for 6 consecutive weeks, with review of the treated skin areas each week. The case studies employed were thus non-randomized but controlled, and each subject was further treated in combination with a film of sunscreen (SPF 30) each morning of the six-week period. Three subjects were used for each formulation provided above, thus resulting in 9 patient subjects for testing purposes. Each subject exhibited improved results subsequent to the treatment period. All but 1 subject patient exhibited improvements during the six-week period of improved skin texture, improved fine lines within the treated skin area, and reduced hyperpigmentation. Such a subject, however, had excessive sun exposure in the skin area affected and photoprotection was minimal in that area as a result. Again, subsequent to the full treatment period, that single subject also exhibited improvements in all areas, such “problems” were solely during the treatment period itself. The subjects all exhibited fading of any post inflammatory pigmentation and reduced appearance of any scarring within the treated skin areas as well. Effectively, then, this all-in-one formulation, whether with regard to any of the types noted above, provided workable, safe, and reliable skin brightening results for all subject patients.

[0034] The preceding examples are set forth to illustrate the principles of the invention, and specific embodiments of operation of the invention. The examples are not intended to limit the scope of the method. Additional embodiments and advantages within the scope of the claimed invention will be apparent to one of ordinary skill in the art.